Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04013191 · ClinicalTrials.gov registry record · Phase 1

A Study to Test the Safety and Tolerability of Single and Multiple Doses of Padsevonil in Adult and Elderly Study Participants

A Phase 1 study, sponsored by UCB Biopharma S.P.R.L..

Completed
Registry status
Phase 1
Development phase
28
Enrollment target

NCT04013191 is a Phase 1 study that has completed, run by UCB Biopharma S.P.R.L.. The registered enrollment target is 28 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04013191, a Phase 1 study, has completed, sponsored by UCB Biopharma S.P.R.L..

COMPLETED
Registry status
Phase 1
Development phase
28 participants
Enrollment target

Study Summary

The purpose of the study is to evaluate the plasma pharmacokinetic of padsevonil in adult and elderly study participants.

Interventions

  • DRUG Padsevonil

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2019-07-09
Est. Completion 2019-10-03
Phase Phase 1

Sponsor

UCB Biopharma S.P.R.L.

23 total trials

What the Registry Record Tells You About NCT04013191

The ClinicalTrials.gov registry entry for NCT04013191 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma S.P.R.L., which has 23 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Padsevonil is the first listed.

NCT04013191 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04013191 about?

NCT04013191 is a clinical study titled "A Study to Test the Safety and Tolerability of Single and Multiple Doses of Padsevonil in Adult and Elderly Study Participants". The purpose of the study is to evaluate the plasma pharmacokinetic of padsevonil in adult and elderly study participants.

What is the current status of trial NCT04013191?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2019-07-09. Estimated completion is 2019-10-03.

What interventions are being tested in trial NCT04013191?

The interventions under investigation include: Padsevonil (DRUG).

Who is sponsoring clinical trial NCT04013191?

This trial is sponsored by UCB Biopharma S.P.R.L., which has 23 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.